RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - IMMUNITA' INNATA E MALATTIA CELIACA
• 2 - MECCANISMI MUCOSALI DI DANNO E RIPARAZIONE NELLE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI (MICI)
• 3 - MALATTIE INFIAMMATORIE INTESTINALI DEL BAMBINO: STUDIO DELLA ESPRESSIONE DI GENI IN RAPPORTO ALLA IMMUNITA' INNATA, ALLA IMMUNITA' RITARDATA E ALLA RISPOSTA ALLA TERAPIA IMMUNOMODULANTE.
• 4 - ANALISI MOLECOLARE E FARMACOLOGICA DI MEDIATORI E TRASPORTATORI COINVOLTI IN PATOLOGIE FUNZIONALI E INFIAMMATORIE INTESTINALI
• 5 - Interazioni fra Mycobacterium Avium Paratuberculosis ed ospite nella patogenesi della malattia di Crohn
• 6 - Il sistema serotoninergico nella fisiopatologia della sindrome dell’intestino irritabile: analisi di meccanismi molecolari e farmacologici finalizzata alla ricerca di nuove opzioni terapeutiche
• 7 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 8 - Studio dei meccanismi etiopatogenetici nel pemfigo
• 9 - Iperlipidemia, Aterosclerosi e Insufficienza Renale
• 10 - Ruolo delle adipochine, citochine infiammatorie e linfociti T regolatori nel determinismo dell’aterosclerosi accelerata e della sindrome metabolica in corso di lupus eritematoso sistemico.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • MEDICINA INTERNA
  • GASTROENTEROLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Sicilia

Bibliografia

References


Pena AS. Genetics of inflammatory bowel diseases--past, present, and future. Dig Dis. 2003;21:85-90.
R.K.Liskens.Huijsdens W,Savelkoul HM,Vandebroucke-Grauls SG,Mewissen GM. The bacterial flora in inflammatory bowel disaease:current insights in pathogenesis and the influence of antibiotics and probiotics.Scand J. Gastroenterol 2001;36 Suppl 234:29-40
Hugot JP,Laurent P.,Gower Rousseau C et al. Mapping of susceptibility locus for Crohn's disease on chromosome 16 Nature 1996;379:821-3
Ogura Y,Bonen D,Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606
Bonen DK, Ogura Y, Nicolae DL. Crohn’s disease-associated NOD2 variants share a signalling defect in response to lypopolysaccharide
and peptidoglycan. Gastroenterology, 2003;124:140-146.
NOD2
Ogura Y ET AL. NOD1/Apaf-1 family member that is restricted to monocyte and activates NF-kB J Bio Chem 2001;276:4812-8
Inohara N et al.Human NOD1 confers responsiveness to bacterial
lipopolysaccharidesJ Biol Chem 2001;276:2551-4
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mahison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science, 1990;249:1431-1433.
Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature, 2000;406:782-787.
Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010-7.


Pouchitis

Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J, 1978;2:85-8.
Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-1209.
Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-309.


Cytomegalovirus
Loftus EV Jr, Alexander GL, Carpenter HA. Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol 1994 Dec; 19 (4): 306-9.
Eyre-Brook IA, Dundas S. Incidence and clinical significance of colonic cytomegalovirus infection in idiopathic inflammatory bowel disease requiring colectomy . Gut 1986; 27:1419-25.
ute ulcerative proctocolitis associated with primary cytomegalovirus infection. Arch Intern Med 1990; vol. 150: 1749-51.
Cottone M, Pietrosi G, Martorana G, et al. Prevalence of ulcerative infection in severe refractory ulcerative and Crohn’ s colitis. Am J Gastroenterol 2001; 96: 773-5.
Robey S.S, Wesley R, Gage A.A. Comparison of immunoperoxidase and DNA in situ hybridation techniques in the diagnosis of cytomegalovirus colitis. AJCP 1988; 89, No 5: 666-671.
Rahbar A, Bostrom L, Lagerstedt U, Magnusson I, Sodeberg-Naucler C and Sundqvist VA.
Evidence of active Cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases. Inflammatory bowel disease 2003; 9:154-61.
– Cotte L, Drouet E, Bailly F, Vitozzi S,et al. Cytomegalovirus DNA level on biopsy specimen during treatment of Cytomegalovirus gastrointestinal disease. Gastroenterology 1996; 111: 439 – 444
1. Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD.Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction.
J Immunol. 1999 May 15;162(10):6107-13.


Intestinal permeability

Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease.Scan J Gastroenrol 1991;27:721-6
Hollenberg MD. Proteinase-mediated signaling: proteinase-activated receptors (PARs) and much more. Life Sci 2003;74:237-46
Perdue M, P Singh, PC Yang, JD Soderholm, V Di Leo, N Bunnett. Proteases regulate intestinal epithelial barrier function by PAR-2 specific and non-specific mechanisms. Gastroenterology 2002; 122 (suppl): A279
Chin AC, Vergnolle N, MacNaughton WK, Wallace JL, Hollenberg MD, Buret AG. Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci U S A 2003;100:11104-9
Kong W, McConalogue K, Khitin LM, Hollenberg MD, Payan DG, Bohm SK, Bunnett NW. 6 Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci U S A 1997;94:8884-9
Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, Dileepan KN. Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res 2001;21:231-40
Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159:3104-3108
Faure GC, Bensoussan-Lejerowicz D, Bene MC, Aubert V, Leclere J. Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells. Clin Immunol Immunopathol 1997; 84: 212-5
Liu Z, Colpaert S, R.D'Haens G, Kasran A, de Boer M, Rutgeerts P, Geboes K, Ceuppens JL. . Hyperexpression of CD40 Ligand (CD154) in Inflammatory Bowel Disease and its Contribution to Pathogenic Cytokine Production. J.Immunol 1999; 163: 4049-57
Sawada-Hase N, Kiyohara T, Miyagawa J, Ueyama H, Nishibayashi H, Murayama Y, Kashihara T, Nakahara M, Miyazaki Y, Kanayama S, Nezu R, Shinomura Y, Matsuzawa Y. An Increased Number of CD40-High Monocytes in Patients with Crohn's Disease. Am J Gastroenterol 2000; 95: 1516-
Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-51
Dubuquoy L, Jansson E, Deeb S, Rakotobe S, Karoui M, Colombel J, Auwerx J, Pettersson S, Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124: 1265-76
Kersten S, Desvergne B, Wahll W. Role of PPARs in health and disease. Nature 2000; 405: 421-4
Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem Biophys Res Commun 2002; 3: 827-31
Wachtershauser A, Loitsh SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun 2000; 272: 380-5
Chen BW, Wang HH, Liu JX, Liu XG. Zinc sulphate solution enema decreases inflammation in experimental colitis in rats. J Gastroenterol Hepatol 1999 Nov;14:1088-92
Pignatelli M. Modulation of cell adhesion during epithelial restitution in the gastrointestinal tract..Yale J Biol Med 199; 69:131-5
Suenaert P, Bulteel V, Lemmens L, Noman, Geypens B, Van Asche G, Geboes K, Ceuppens JL, Rutgeerts. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am. J. Gastroenterology2002;97:2000-2004.
Wild GE, Waschke KA, Bitton A, Thomson ABR. The mechanisms of prednisone inhibition of inflammation in Crohn’s disease involve changes in intestinal permeability, mucosal TNF-alpha production and nuclear factor kappa B expresssion. Aliment. Pharmacol. Ther. 2003;18:309-317
Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, Said HM. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappaB activation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;286:G367-G376.
Han X, Fink MP, Uchiyama T, Yang R, Delude RL. Increased iNOS activity is essential for hepatic epithelial tight junction dysfunction in endotoxinemic mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;286:G126-G136

Parole Chiave

BATTERI; PROBIOTICI; MALATTIE INFIAMMATORIE CRONICHE DELL'INTESTINO; CITOMEGALOVIRUS; POUCHITE; PERMEABILITÀ INTESTINALE; INFLIXIMAB; GENETICA; PAR